AIMS: Natriuretic peptides including N-terminal pro-B-type natriuretic peptide (NT-proBNP) are established biomarkers in heart failure. However, their prognostic value in the general population is less well established. The purpose of our study was to investigate the prognostic properties of NT-proBNP for death and cardiovascular (CV) events in the general population. METHODS AND RESULTS: In the population-based Prevention of Renal and Vascular End-stage Disease (PREVEND) study, 8383 subjects were prospectively followed for a median period of 7.5 years. There were 4181 (49.9%) males and 4202 (50.1%) females, mean age was 49.3 +/- 12.7 years (range 28-75). Median NT-proBNP at baseline was 37.7 pg/mL (IQR 16.8-73.8). All-cause death occurred in 437 (5.2%) subjects and there were 557 (6.6%) CV events. Higher levels of plasma NT-proBNP were related to higher event rates. When adjusted for age, gender, and other relevant covariates, each doubling of NT-proBNP remained significantly associated with a 22% increased risk for all-cause mortality (P < 0.001) and a 16% increased risk of CV events (P < 0.001). CONCLUSION: In this large community-based cohort, plasma NT-proBNP was a strong predictor of death and a wide range of CV events.
AIMS: Natriuretic peptides including N-terminal pro-B-type natriuretic peptide (NT-proBNP) are established biomarkers in heart failure. However, their prognostic value in the general population is less well established. The purpose of our study was to investigate the prognostic properties of NT-proBNP for death and cardiovascular (CV) events in the general population. METHODS AND RESULTS: In the population-based Prevention of Renal and Vascular End-stage Disease (PREVEND) study, 8383 subjects were prospectively followed for a median period of 7.5 years. There were 4181 (49.9%) males and 4202 (50.1%) females, mean age was 49.3 +/- 12.7 years (range 28-75). Median NT-proBNP at baseline was 37.7 pg/mL (IQR 16.8-73.8). All-cause death occurred in 437 (5.2%) subjects and there were 557 (6.6%) CV events. Higher levels of plasma NT-proBNP were related to higher event rates. When adjusted for age, gender, and other relevant covariates, each doubling of NT-proBNP remained significantly associated with a 22% increased risk for all-cause mortality (P < 0.001) and a 16% increased risk of CV events (P < 0.001). CONCLUSION: In this large community-based cohort, plasma NT-proBNP was a strong predictor of death and a wide range of CV events.
Authors: Navin Suthahar; Wouter C Meijers; Jennifer E Ho; Ron T Gansevoort; Adriaan A Voors; Peter van der Meer; Stephan J L Bakker; Stephane Heymans; Vanessa van Empel; Blanche Schroen; Pim van der Harst; Dirk J van Veldhuisen; Rudolf A de Boer Journal: Eur J Heart Fail Date: 2018-06-01 Impact factor: 15.534
Authors: Wassim W Labaki; Meng Xia; Susan Murray; Jeffrey L Curtis; R Graham Barr; Surya P Bhatt; Eugene R Bleecker; Nadia N Hansel; Christopher B Cooper; Mark T Dransfield; J Michael Wells; Eric A Hoffman; Richard E Kanner; Robert Paine; Victor E Ortega; Stephen P Peters; Jerry A Krishnan; Russell P Bowler; David J Couper; Prescott G Woodruff; Fernando J Martinez; Carlos H Martinez; MeiLan K Han Journal: Respir Med Date: 2018-06-05 Impact factor: 3.415
Authors: Kaffer Kara; Amir A Mahabadi; Marie H Geisel; Nils Lehmann; Hagen Kälsch; Marcus Bauer; Till Neumann; Nico Dragano; Susanne Moebus; Stefan Möhlenkamp; Karl-Heinz Jöckel; Raimund Erbel Journal: Clin Res Cardiol Date: 2013-10-15 Impact factor: 5.460
Authors: Biniyam G Demissei; Douwe Postmus; Mattia A Valente; Pim van der Harst; Wijk H van Gilst; Edwin R Van den Heuvel; Hans L Hillege Journal: Eur J Epidemiol Date: 2014-11-07 Impact factor: 8.082
Authors: Andrew C Don-Wauchope; Pasqualina L Santaguida; Robert McKelvie; Judy A Brown; Mark Oremus; Usman Ali; Amy Bustamam; Nazmul Sohel; Stephen A Hill; Ronald A Booth; Cynthia Balion; Parminder Raina Journal: Heart Fail Rev Date: 2014-08 Impact factor: 4.214
Authors: Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Laura M G Meems; Frank P Brouwers; Michel M Joosten; Hiddo J Lambers Heerspink; Dick de Zeeuw; Stephan J L Bakker; Ron T Gansevoort; Wiek H van Gilst; Pim van der Harst; Rudolf A de Boer Journal: ESC Heart Fail Date: 2016-04-26
Authors: Oludamilola W Oluleye; Aaron R Folsom; Vijay Nambi; Pamela L Lutsey; Christie M Ballantyne Journal: Ann Epidemiol Date: 2012-12-08 Impact factor: 3.797